Union of forces advances myeloma care

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.

Original languageEnglish (US)
Pages (from-to)674-675
Number of pages2
JournalBlood
Volume116
Issue number5
DOIs
StatePublished - Aug 5 2010

Fingerprint

Joining
Blood
Pharmaceutical Preparations
Industry
Therapeutics
Bortezomib
lenalidomide

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Union of forces advances myeloma care. / Stewart, Alexander Keith.

In: Blood, Vol. 116, No. 5, 05.08.2010, p. 674-675.

Research output: Contribution to journalArticle

Stewart, Alexander Keith. / Union of forces advances myeloma care. In: Blood. 2010 ; Vol. 116, No. 5. pp. 674-675.
@article{87467d835d724480b0eac33ccf371710,
title = "Union of forces advances myeloma care",
abstract = "In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.",
author = "Stewart, {Alexander Keith}",
year = "2010",
month = "8",
day = "5",
doi = "10.1182/blood-2010-04-281212",
language = "English (US)",
volume = "116",
pages = "674--675",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "5",

}

TY - JOUR

T1 - Union of forces advances myeloma care

AU - Stewart, Alexander Keith

PY - 2010/8/5

Y1 - 2010/8/5

N2 - In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.

AB - In this issue of Blood, Richardson et al report on a landmark treatment regimen for newly diagnosed myeloma patients that for the first time combines lenalidomide and bortezomib. This effort required a team approach comprising 2 competing pharmaceutical companies (joining forces to study this promising regimen) and multiple academic medical centers.

UR - http://www.scopus.com/inward/record.url?scp=77956544163&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77956544163&partnerID=8YFLogxK

U2 - 10.1182/blood-2010-04-281212

DO - 10.1182/blood-2010-04-281212

M3 - Article

C2 - 20688962

AN - SCOPUS:77956544163

VL - 116

SP - 674

EP - 675

JO - Blood

JF - Blood

SN - 0006-4971

IS - 5

ER -